Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin

Status Completed

Clinical Trial Summary

Assessment of the safety and efficacy of intramuscular (IM) administration of a recombinant adenoassociated virus (rAAV) alpha-1 antitrypsin (AAT) vector (rAAV1-CB-hAAT) in AAT-deficient adults at three dosage levels [6.0 × 10e11, 1.9 × 10e12 and 6.0 × 10e12 vector genome particles (vg) per kg body weight].

Funding Sources - The FDA Office of Orphan Products Development and NIH National Heart, Lung, and Blood Institute

Clinical Trial Description

The study is a non-randomized, open-label, multi-center, sequential, three-arm, Phase 2 clinical trial evaluating the safety and efficacy of administration of a rAAV1-CB-hAAT vector administered by IM injection. Each participant will receive rAAV1-CB-hAAT on a single occasion. Three groups of three subjects each will receive rAAV1-CB-hAAT at dosage levels of 6 x 10e11 vg/kg, 1.9 x 10e12 vg/kg or 6 x 10e12 vg/kg by IM injection. Subjects in group 1 will receive a total of 10 IM injections distributed across a single muscle site, subjects in group 2 will receive a total of 32 IM injections distributed across three muscle sites, and subjects in group 3 will receive 100 IM injections distributed across 10 muscle sites. Each injection will be given in a volume of 1.35 mL, at the appropriate vector concentration to achieve the desired total vector dose.

The three groups were enrolled sequentially, with review of safety data by a Data and Safety Monitoring Board before enrollment of each higher dosage level group.

Safety was monitored by evaluation of adverse events, hematology and clinical chemistry parameters, histological examination of muscle biopsies, and measurement of serum antibodies to AAT. Efficacy was measured by evaluation of serum concentrations of M-specific AAT and total AAT, and serum AAT phenotype determined on isoelectric focusing gels. Additional information collected included presence of the vector in blood or semen, changes in serum anti-AAV antibody titers, and changes in T cell responses to AAV and AAT. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01054339
Study type	Interventional
Source	Applied Genetic Technologies Corp
Contact
Status	Completed
Phase	Phase 2
Start date	June 2010
Completion date	October 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02547532` - Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT00005292` - Alpha1-antitrypsin Deficiency Registry	N/A
Withdrawn	`NCT02900183` - Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels	Phase 2
Terminated	`NCT02502201` - Environment Effect on Six-Minute Walk Test Performance	N/A
Completed	`NCT01810458` - Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
Active, not recruiting	`NCT04262284` - Respreeza® Self-administration and Learning Program (AmAREtTI Study)
Recruiting	`NCT06186492` - A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)	Phase 1
Completed	`NCT03815396` - Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency	Phase 1
Completed	`NCT03008915` - Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency	Phase 2
Completed	`NCT01419158` - Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)	N/A
Recruiting	`NCT00500123` - The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
Completed	`NCT05727800` - A Phase 1, First-in-human Study of VX-668	Phase 1
Active, not recruiting	`NCT05643495` - A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype	Phase 2
Terminated	`NCT02363946` - A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)	Phase 1
Completed	`NCT02810327` - Alpha-1 Carrier Genomics Study
Completed	`NCT03804021` - Long-Term Follow-up Study of ADVM-043
Active, not recruiting	`NCT02014415` - Alpha-1 Antitrypsin Deficiency Adult Liver Study
Terminated	`NCT01241942` - Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability	N/A
Recruiting	`NCT01851642` - Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms